User profiles for Eduardo Sprinz
 | Eduardo SprinzHospital de Clínicas de Porto Alegre - FAMED - UFRGS Verified email at hcpa.edu.br Cited by 13845 |
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa …
Background A safe and efficacious vaccine against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …
[HTML][HTML] Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a …
Background The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo …
Background Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-inflammatory
properties. This study evaluates the efficacy and safety of baricitinib in combination …
properties. This study evaluates the efficacy and safety of baricitinib in combination …
Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries.
Background Highly active antiretroviral therapy (HAART) is being scaled up in developing
countries. We compared baseline characteristics and outcomes during the first year of HAART …
countries. We compared baseline characteristics and outcomes during the first year of HAART …
[PDF][PDF] Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries
OBJECTIVE: To analyse the early loss of patients to antiretroviral therapy (ART) programmes
in resource-limited settings. METHODS: Using data on 5491 adult patients starting ART (…
in resource-limited settings. METHODS: Using data on 5491 adult patients starting ART (…
Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial
…, DIM de Salazar, CA Rodríguez, E Sprinz… - The Lancet, 2022 - thelancet.com
Background A range of safe and effective vaccines against SARS CoV 2 are needed to
address the COVID 19 pandemic. We aimed to assess the safety and efficacy of the COVID-19 …
address the COVID 19 pandemic. We aimed to assess the safety and efficacy of the COVID-19 …
Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration
…, M Schechter, SH Tuboi, E Sprinz… - Journal of women's …, 2008 - liebertpub.com
Aims: To compare the gender distribution of HIV-infected adults receiving highly active
antiretroviral treatment (HAART) in resource-constrained settings with estimates of the gender …
antiretroviral treatment (HAART) in resource-constrained settings with estimates of the gender …
Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies
Background: Few data are available on the long-term immunologic response to antiretroviral
therapy (ART) in resource-limited settings, where ART is being rapidly scaled up using a …
therapy (ART) in resource-limited settings, where ART is being rapidly scaled up using a …
[PDF][PDF] Exercise training in HIV-1-infected individuals with dyslipidemia and lipodystrophy
L Terry, E Sprinz, R Stein, NB Medeiros… - Medicine & Science …, 2006 - pacificpapermill.com
… LUCRECIA TERRY1, EDUARDO SPRINZ2, RICARDO STEIN1, NICIA B. MEDEIROS2,
JARBAS OLIVEIRA2, and JORGE P. RIBEIRO1,3 … SPRINZ, R. STEIN, NB MEDEIROS, J …
JARBAS OLIVEIRA2, and JORGE P. RIBEIRO1,3 … SPRINZ, R. STEIN, NB MEDEIROS, J …
[HTML][HTML] Comorbidity is more common and occurs earlier in persons living with HIV than in HIV-uninfected matched controls, aged 50 years and older: a cross …
RA Maciel, HM Klück, M Durand, E Sprinz - International Journal of …, 2018 - Elsevier
Objectives At present, data are limited on the comorbidity profiles associated with aging people
with HIV in the developing world, where most such people live. The aim of this study was …
with HIV in the developing world, where most such people live. The aim of this study was …
